SELARL PHARMACIE FRANCOISE DETAVERNIER is a French company
founded 18 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in LANDAS (59310),
this company of category PME
shows in 2023 a revenue of 2.5 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE FRANCOISE DETAVERNIER (SIREN 502148059)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue
N/C
N/C
2 463 564 €
N/C
N/C
N/C
N/C
1 828 299 €
1 809 414 €
Net income
84 837 €
160 757 €
155 764 €
127 899 €
133 645 €
136 498 €
142 693 €
124 844 €
155 596 €
EBITDA
N/C
N/C
195 861 €
N/C
N/C
N/C
N/C
170 476 €
222 775 €
Net margin
N/C
N/C
6.3%
N/C
N/C
N/C
N/C
6.8%
8.6%
Revenue and income statement
In 2025, SELARL PHARMACIE FRANCOISE DETAVERNIER generates positive net income of 85 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 156 k€ -> 85 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
84 837 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 86%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
0.035%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
86.285%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
14.109
8.596
2.971
0.048
0.055
0.055
0.058
0.046
0.035
Financial autonomy
78.569
79.696
86.672
87.958
88.214
86.147
86.455
87.432
86.285
Repayment capacity
1.133
0.825
None
None
None
None
0.006
None
None
Cash flow / Revenue
8.699%
7.309%
None%
None%
None%
None%
6.115%
None%
None%
Sector positioning
Debt ratio
0.042025
2023
2024
2025
Q1: 13.57
Med: 49.47
Q3: 128.28
Excellent
In 2025, the debt ratio of SELARL PHARMACIE FRANCOIS... (0.04) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
86.28%2025
2023
2024
2025
Q1: 33.69%
Med: 53.88%
Q3: 72.26%
Excellent+11 pts over 3 years
In 2025, the financial autonomy of SELARL PHARMACIE FRANCOIS... (86.3%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Repayment capacity
0.01 years2023
2023
Q1: 0.95 years
Med: 3.58 years
Q3: 7.48 years
Excellent
In 2023, the repayment capacity of SELARL PHARMACIE FRANCOIS... (0.01) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 210.68. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
240.246
189.363
203.226
188.084
206.627
199.783
222.609
251.669
210.682
Interest coverage
3.385
2.161
None
None
None
None
0.0
None
None
Sector positioning
Liquidity ratio
210.682025
2023
2024
2025
Q1: 131.48
Med: 182.6
Q3: 258.72
Good
In 2025, the liquidity ratio of SELARL PHARMACIE FRANCOIS... (210.68) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Interest coverage
0.0x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Average
In 2023, the interest coverage of SELARL PHARMACIE FRANCOIS... (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SELARL PHARMACIE FRANCOISE DETAVERNIER
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
114 644 €
149 171 €
0 €
0 €
0 €
0 €
161 832 €
0 €
0 €
Inventory turnover (days)
24
24
0
0
0
0
19
0
0
Customer payment term (days)
5
5
0
0
0
0
7
0
0
Supplier payment term (days)
33
48
0
0
0
0
35
0
0
Positioning of SELARL PHARMACIE FRANCOISE DETAVERNIER in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SELARL PHARMACIE FRANCOISE DETAVERNIER is estimated at
1 347 645 €
(range 914 518€ - 2 114 641€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
914k€1347k€2114k€
1 347 645 €Range: 914 518€ - 2 114 641€
NAF 5 année 2025
Valuation method used
Net Income Multiple
84 837 €
×
15.9x
=1 347 646 €
Range: 914 519€ - 2 114 642€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE FRANCOISE DETAVERNIER with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE FRANCOISE DETAVERNIER
What is the revenue of SELARL PHARMACIE FRANCOISE DETAVERNIER ?
The revenue of SELARL PHARMACIE FRANCOISE DETAVERNIER in 2023 is 2.5 M€.
Is SELARL PHARMACIE FRANCOISE DETAVERNIER profitable?
Yes, SELARL PHARMACIE FRANCOISE DETAVERNIER generated a net profit of 85 k€ in 2025.
Where is the headquarters of SELARL PHARMACIE FRANCOISE DETAVERNIER ?
The headquarters of SELARL PHARMACIE FRANCOISE DETAVERNIER is located in LANDAS (59310), in the department Nord.
Where to find the tax return of SELARL PHARMACIE FRANCOISE DETAVERNIER ?
The tax return of SELARL PHARMACIE FRANCOISE DETAVERNIER is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE FRANCOISE DETAVERNIER operate?
SELARL PHARMACIE FRANCOISE DETAVERNIER operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart